Herombopag for the Treatment of Persistent Thrombocytopenia Following Hematopoietic Stem Cell Transplantation

Overview

Journal Ann Hematol

Specialty Hematology

Date 2024 Mar 27

PMID 38536476

Authors

Miao Zhou

Tongyu Li

Ping Zhang

Yanli Lai

Lixia Sheng

Guifang Ouyang

Affiliations

Soon will be listed here.

Abstract

Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) stands as a pivotal treatment for hematologic malignancies, often considered the sole effective treatment option. A frequent complication following allo-HSCT is poor graft function (PGF), with one of its primary manifestations being persistent thrombocytopenia (PT), comprising prolonged isolated thrombocytopenia (PIT) and secondary failure of platelet recovery (SFPR). Conventional treatment methods have had poor efficacy and a high transplantation-associated mortality rate. In recent years, the efficacy of eltrombopag has been reported in the treatment of post-transplantation PT, and additional thrombopoietin receptor agonists (TPO-RA) have been developed. Herombopag is a next-generation TPO-RA which has strong proliferation-promoting effects on human TPO-R-expressing cells (32D-MPL) and hematopoietic progenitor cells in vitro. We reviewed eighteen patients with transplantation-associated thrombocytopenia who received herombopag when eltrombopag was ineffective or poorly tolerated and evaluated its efficacy including effects on survival. Herombopag was administered at a median time of 197 days post-transplantation. Six patients achieved complete response (CR), with a median time to CR of 56 days. Five patients achieved partial response (PR), and the median time to PR was 43 days. Seven patients were considered to have no response (NR). The overall response (OR) rate was 61.1%, and the cumulative incidence (CI) of OR was 90.2%. No patients developed herombopag-associated grade 3-4 toxicity. The median follow-up period was 6.5 months. Twelve patients survived and six patients died, with an overall survival rate of 66.7%. This is the first study to demonstrate the efficacy and safety of herombopag in transplantation-associated thrombocytopenia after failing eltrombopag, introducing a new approach in the treatment of PT following allo-HSCT.

References

Niederwieser D, Baldomero H, Szer J, Gratwohl M, Aljurf M, Atsuta Y . Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey. Bone Marrow Transplant. 2016; 51(6):778-85. PMC: 4889523. DOI: 10.1038/bmt.2016.18. View

Gratwohl A, Pasquini M, Aljurf M, Atsuta Y, Baldomero H, Foeken L . One million haemopoietic stem-cell transplants: a retrospective observational study. Lancet Haematol. 2015; 2(3):e91-100. DOI: 10.1016/S2352-3026(15)00028-9. View

Yamazaki R, Kuwana M, Mori T, Okazaki Y, Kawakami Y, Ikeda Y . Prolonged thrombocytopenia after allogeneic hematopoietic stem cell transplantation: associations with impaired platelet production and increased platelet turnover. Bone Marrow Transplant. 2006; 38(5):377-84. DOI: 10.1038/sj.bmt.1705444. View

Kuzmina Z, Eder S, Bohm A, Pernicka E, Vormittag L, Kalhs P . Significantly worse survival of patients with NIH-defined chronic graft-versus-host disease and thrombocytopenia or progressive onset type: results of a prospective study. Leukemia. 2011; 26(4):746-56. DOI: 10.1038/leu.2011.257. View

Kong Y, Song Y, Tang F, Zhao H, Chen Y, Han W . N-acetyl-L-cysteine improves mesenchymal stem cell function in prolonged isolated thrombocytopenia post-allotransplant. Br J Haematol. 2018; 180(6):863-878. DOI: 10.1111/bjh.15119. View

Sun Y, Kong Y, Zhang X, Wang Y, Shi M, Song Y . A novel recombinant human thrombopoietin for treating prolonged isolated thrombocytopenia after allogeneic stem cell transplantation. Platelets. 2018; 30(8):994-1000. DOI: 10.1080/09537104.2018.1557613. View

Bolwell B, Pohlman B, Sobecks R, Andresen S, Brown S, Rybicki L . Prognostic importance of the platelet count 100 days post allogeneic bone marrow transplant. Bone Marrow Transplant. 2003; 33(4):419-23. DOI: 10.1038/sj.bmt.1704330. View

Zaja F, Geromin A, Patriarca F, Puglisi S, Cerno M, Sperotto A . Prognostic significance of delayed thrombocytopenia after allogeneic stem cell transplant. Am J Hematol. 2011; 86(9):790-2. DOI: 10.1002/ajh.22086. View

Di Buduo C, Currao M, Pecci A, Kaplan D, Balduini C, Balduini A . Revealing eltrombopag's promotion of human megakaryopoiesis through AKT/ERK-dependent pathway activation. Haematologica. 2016; 101(12):1479-1488. PMC: 5479602. DOI: 10.3324/haematol.2016.146746. View

10.

Wen B, Zhang X, Chen S, Fan J, Yang S, Cai Y . Oral eltrombopag versus subcutaneous recombinant human thrombopoietin for promoting platelet engraftment after allogeneic stem cell transplantation: A prospective, non-inferiority, randomized controlled trial. Hematol Oncol. 2022; 40(4):777-786. PMC: 9790607. DOI: 10.1002/hon.3017. View

11.

Masetti R, Vendemini F, Quarello P, Girardi K, Prete A, Fagioli F . Eltrombopag for thrombocytopenia following allogeneic hematopoietic stem cell transplantation in children. Pediatr Blood Cancer. 2020; 67(5):e28208. DOI: 10.1002/pbc.28208. View

12.

Rivera D, Bastida J, Lopez-Corral L, Sanchez-Guijo F, Cabrero M, Martin A . Usefulness of eltrombopag for treating thrombocytopenia after allogeneic stem cell transplantation. Bone Marrow Transplant. 2018; 54(5):757-761. DOI: 10.1038/s41409-018-0368-1. View

13.

Syed Y . Hetrombopag: First Approval. Drugs. 2021; 81(13):1581-1585. DOI: 10.1007/s40265-021-01575-1. View

14.

Li T, Liu Q, Pu T, Liu J, Zhang A . Efficacy and safety of thrombopoietin receptor agonists in children and adults with persistent and chronic immune thrombocytopenia: a meta-analysis. Expert Opin Pharmacother. 2023; 24(6):763-774. DOI: 10.1080/14656566.2023.2198089. View

15.

Zheng X, Zhang H, Guo W, Cao Y, Liu X, Zhai W . Herombopag promotes platelet engraftment and decreases platelet transfusion after allogeneic hematopoietic stem cell transplantation. Eur J Haematol. 2023; 110(5):527-533. DOI: 10.1111/ejh.13925. View

16.

Broudy V, Lin N . AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl. Cytokine. 2003; 25(2):52-60. DOI: 10.1016/j.cyto.2003.05.001. View

17.

Cheloff A, Al-Samkari H . Avatrombopag for the treatment of immune thrombocytopenia and thrombocytopenia of chronic liver disease. J Blood Med. 2019; 10:313-321. PMC: 6733339. DOI: 10.2147/JBM.S191790. View

18.

Xie C, Zhao H, Bao X, Fu H, Lou L . Pharmacological characterization of hetrombopag, a novel orally active human thrombopoietin receptor agonist. J Cell Mol Med. 2018; 22(11):5367-5377. PMC: 6201220. DOI: 10.1111/jcmm.13809. View

19.

Yang G, Huang R, Yang S, Zhang X, Yang X, Chen H . Effect of postdose fasting duration on hetrombopag olamine pharmacokinetics and pharmacodynamics in healthy volunteers. Br J Clin Pharmacol. 2020; 86(8):1528-1536. PMC: 7373699. DOI: 10.1111/bcp.14259. View

20.

Mei H, Liu X, Zhou H, Feng Y, Gao G, Cheng P . A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia. J Hematol Oncol. 2021; 14(1):37. PMC: 7905908. DOI: 10.1186/s13045-021-01047-9. View